07 October 2024
07 October 2024
WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical director.
The rise in mRNA pharmaceuticals鈥� licensing agreement values suggests that this field will remain a major area for innovation and investment.
The acquisition by PLG adds valuable expertise to its portfolio, supporting biopharmaceutical companies in drug development.
Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue鈥�
Two years after the US agency placed the partial clinical hold, Avidity can resume the research of del-desiran as a treatment for myotonic dystrophy type 1.
The authorisation expands the range of clinical uses for Illuccix, distributed by Isologic.
The company's OKI-219 has shown considerable specificity in targeting the mutant oncogene.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional migraine markets through 2033. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market鈥檚 unmet needs and opportunities will help in determining potential business possibilities.
Give your business an edge with our leading industry insights.
